Raymond James Upgrades Dyne Therapeutics to Strong Buy, Raises Price Target to $35
2025-08-25 22:47
Raymond James analyst Martin Auster upgrades Dyne Therapeutics (NASDAQ: DYN) from Outperform to Strong Buy and raises the price target from $31 to $35.